GIST Oral Paclitaxel(Liporaxel)

This Phase 2 study tests Liporaxel — an oral (pill) form of paclitaxel chemotherapy — as a treatment for patients with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to three prior standard targeted therapies (imatinib, sunitinib, and regorafenib). GIST is a type of tumor in the digestive tract, and most patients eventually develop resistance to the standard drugs, leaving few options. Eligible participants are adults aged 20 or older with histologically confirmed advanced or metastatic GIST, who have failed all three prior treatments and whose tumors show low expression of a resistance protein called P-glycoprotein; those with severe heart disease, active infections, or prior paclitaxel treatment for GIST are excluded. Participation involves taking Liporaxel orally according to a set schedule, with regular imaging, blood tests, and clinic visits to monitor tumor response and side effects. This summary was prepared using AI to help patients understand the study in plain language.